A comparative study of the hypoxia PET tracers [18F]HX4, [18F]FAZA, and [18F]FMISO in a preclinical tumor model

International Journal of Radiation Oncology Biology Physics

Volumn 91, Issue 2, 2015, Pages 351-359

  Peeters, Sarah G J A ^a   Zegers, Catharina M L ^a   Lieuwes, NatasjaG ^a   Van Elmpt, Wouter ^a   Eriksson, Jonas ^b   Van Dongen, Guus A M S ^b   Dubois, Ludwig ^a   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BREEDER REACTORS; COMPUTERIZED TOMOGRAPHY; OXYGEN; TUMORS;

COMPARATIVE STUDIES; CORRELATION COEFFICIENT; METHODS AND MATERIALS; OXYGEN MODIFICATIONS; POSITRON EMISSION TOMOGRAPHY (PET); PRECLINICAL STUDIES; SIMILARITY COEFFICIENTS; STANDARDIZED UPTAKE VALUES;

POSITRON EMISSION TOMOGRAPHY;

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; CARBOGEN; FLUOROAZOMYCIN ARABINOSIDE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; NICOTINAMIDE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; FLUOROAZOMYCIN ARABINOSIDE; HX4 COMPOUND; IMIDAZOLE DERIVATIVE; MISONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; OXYGEN; TRIAZOLE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; HYPOXIA; IMAGE ANALYSIS; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; OXYGEN BREATHING; OXYGEN CONCENTRATION; OXYGEN THERAPY; PET-CT SCANNER; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RHABDOMYOSARCOMA; SENSITIVITY ANALYSIS; TUMOR GROWTH; TUMOR TO BLOOD RATIO; TUMOR VOLUME; VOXEL BASED MORPHOMETRY; WISTAR ALBINO GLAXO RAT; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; CELL HYPOXIA; COMPUTER SIMULATION; DIAGNOSTIC USE; METABOLISM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RAT; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; COMPUTER SIMULATION; IMIDAZOLES; MISONIDAZOLE; MODELS, BIOLOGICAL; NITROIMIDAZOLES; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; REPRODUCIBILITY OF RESULTS; RHABDOMYOSARCOMA; SENSITIVITY AND SPECIFICITY; TRIAZOLES;

EID: 84922587421     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.09.045     Document Type: Article

References (35)

1. Hammond EM, Asselin MC, Forster D, et al. The meaning, measurement and modification of hypoxia in the laboratory and the clinic. Clin Oncol (R Coll Radiol) 2014;26:277-288.
2. Horsman MR, Mortensen LS, Petersen JB, et al. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 2012;9:674-687.
3. Brown JM, Giaccia AJ. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-1416.
4. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008;49(suppl 2):129S-148S.
5. 18f] fmiso for pet-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. Eur J Nucl Med Mol Imaging 2009;36:209-218.
6. 18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004;31:513-520.
7. 18F]-MISO in rodent tumor models. Radiother Oncol 2008;89:353-360.
8. 18F]FAZA-First small animal PET results. J Pharm Pharm Sci 2007;10:203-211.
9. 18F]hx4, a promising hypoxia marker for pet imaging. Proc Natl Acad Sci USA 2011;108:14620-14625.
10. Carlin S, Zhang H, Reese M, et al. A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers. J Nucl Med 2014;55:515-521.
11. Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with 18f-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253-260.
12. Mortensen LS, Johansen J, Kallehauge J, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial. Radiother Oncol 2012;105:14-20.
13. 18f]hx4: A phase i trial. Eur J Nucl Med Mol Imaging 2010;37:1663-1668.
14. 18F-HX4 in monkeys and humans determined by using whole-body PET/CT. Nucl Med Commun 2010;31:1016-1024.
15. 18F]fluoromisonidazole. Appl Radiat Isot 1993;44:1085-1091.
16. 18F]FAZA: Reaction parameters and automation. Appl Radiat Isot 2005;62:897-901.
17. Walsh JC, Kolb HC. Applications of click chemistry in radiopharmaceutical development. Chimia (Aarau) 2010;64:29-33.
18. 18)f]fluoromisonidazole pet and immunohistochemistry. Br J Cancer 2004;91:1947-1954.
19. Servagi-Vernat S, Differding S, Hanin FX, et al. A prospective clinical study of F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. Eur J Nucl Med Mol Imaging 2014;41:1544-1552.
20. 18f]faza PET in head and neck cancer patients: A pilot study. Eur J Nucl Med Mol Imaging 2007;34:1566-1575.
21. Trinkaus ME, Blum R, Rischin D, et al. Imaging of hypoxia with 18f-faza PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy. J Med Imaging Radiat Oncol 2013;57:475-481.
22. Zegers CM, van Elmpt W, Wierts R, et al. Hypoxia imaging with [(1) (8) f]hx4 pet in nsclc patients: Defining optimal imaging parameters. Radiother Oncol 2013;109:58-64.
23. 18F]FMISO-PET in HNSCC. When is the contrast best? Nuklearmedizin 2011;50:22-27.
24. 18F-FMISO. Nucl Med Commun 2012;33:1096-1102.
25. 18F]EF3: Improvement of the tumour-tobackground ratio in a mouse tumour model. Eur J Nucl Med Mol Imaging 2007;34:1348-1354.
26. 18F]FMISO-PET in head and neck cancer: Potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol 2011;101:369-375.
27. Thorwarth D, Eschmann SM, Paulsen F, et al. Hypoxia dose painting by numbers: A planning study. Int J Radiat Oncol Biol Phys 2007;68:291-300.
28. 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med 2013;54:201-207.
29. 18F]fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008;70:235-242.
30. 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy. Radiother Oncol 2013;108:511-516.
31. Busk M, Mortensen LS, Nordsmark M, et al. PET hypoxia imaging with FAZA: Reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice. Eur J Nucl Med Mol Imaging 2013;40:186-197.
32. Brown M, Henry S. Kaplan distinguished scientist award lecture 2007. The remarkable yin and yang of tumour hypoxia. Int J Radiat Biol 2010;86:907-917.
33. Horsman MR, Overgaard J. Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen. Radiother Oncol 2004;70:301-309.
34. 18F-fluoroazomycin arabinoside. J Nucl Med 2005;46:106-113.
35. 18F]fluoromisonidazole positron emission tomography. Int J Oncol 2007;30:873-881.